These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32022907)

  • 1. Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself.
    Butler SS; Mahal BA
    Cancer; 2020 May; 126(10):2321-2322. PubMed ID: 32022907
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself.
    Joshi SS; Filson CP
    Cancer; 2020 May; 126(10):2322-2323. PubMed ID: 32022901
    [No Abstract]   [Full Text] [Related]  

  • 3. The golden rule: Do not do to others what you do not want done to yourself.
    Takahashi TF
    Cancer; 2020 May; 126(10):2319-2320. PubMed ID: 32022926
    [No Abstract]   [Full Text] [Related]  

  • 4. Obesity and aggressive prostate cancer.
    Lehrer SP
    Cancer; 2020 May; 126(10):2319. PubMed ID: 32022896
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Takeshi Takahashi's Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
    Van Poppel H; Roobol MJ
    Eur Urol; 2022 Jan; 81(1):e23-e24. PubMed ID: 34756628
    [No Abstract]   [Full Text] [Related]  

  • 6. The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?
    Daniels JP; Freedland SJ; Gresham G
    J Natl Cancer Inst; 2023 Dec; 115(12):1448-1450. PubMed ID: 37587090
    [No Abstract]   [Full Text] [Related]  

  • 7. [Epidemiology of prostate cancer in China: an overview and clinical implication].
    Ye D; Zhu Y
    Zhonghua Wai Ke Za Zhi; 2015 Apr; 53(4):249-52. PubMed ID: 26269155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening and the golden rule of humanity.
    Takahashi T
    BMJ; 2023 Jun; 381():1390. PubMed ID: 37364902
    [No Abstract]   [Full Text] [Related]  

  • 9. Should you skip your PSA test? The science is uncertain for now, so arm yourself with deep knowledge of the pros and cons of prostate cancer screening.
    Harv Mens Health Watch; 2012 Oct; 17(3):1, 7. PubMed ID: 23175860
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate Cancer Statistics: Anything You Want Them To Be.
    Gomella LG
    Can J Urol; 2017 Feb; 24(1):8603-8604. PubMed ID: 28263123
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing the harms and benefits of early detection of prostate cancer.
    van Leeuwen PJ; Connolly D; Tammela TL; Auvinen A; Kranse R; Roobol MJ; Schroder FH; Gavin A
    Cancer; 2010 Oct; 116(20):4857-65. PubMed ID: 20839233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not?
    Downer MK; Stampfer MJ; Cooperberg MR
    JAMA Oncol; 2017 Dec; 3(12):1623-1624. PubMed ID: 28494051
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol 2021;80:703-711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?
    Takahashi T
    Eur Urol; 2022 Jan; 81(1):e22. PubMed ID: 34716050
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment.
    Rais-Bahrami S; Moreira DM
    Urology; 2012 Jun; 79(6):1334-5; author reply 1335. PubMed ID: 22656413
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 16. Summaries for patients. Screening smarter, not harder, for prostate cancer.
    Ann Intern Med; 2013 Feb; 158(3):I-30. PubMed ID: 23381056
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation : analysis of trends over time.
    Scosyrev E; Messing EM
    Cancer; 2013 Mar; 119(5):1113-4. PubMed ID: 23097014
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
    Joshi SS; Filson CP
    Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer screening practice and knowledge in Rhode Island.
    Glicksman AS; Meyer A; Cullinen K
    Med Health R I; 2009 Feb; 92(2):65-6. PubMed ID: 19288690
    [No Abstract]   [Full Text] [Related]  

  • 20. Screening for prostate cancer: an updated review.
    Marta GN; Hanna SA; Fernandes da Silva JL; Carvalho Hde A
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):101-8. PubMed ID: 23259431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.